| Mrs Portia S Carr, MS,CCC-SLP | |
|
7327 Worth Ave E, Benton, AR 72019-6895 | |
| (501) 773-7155 | |
| Not Available |
| Full Name | Mrs Portia S Carr |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 7327 Worth Ave E, Benton, Arkansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093999518 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SP#2606 (Arkansas) | Primary |
| Provider Name | Infinity Therapy, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1295197135 PECOS PAC ID: 3173856747 Enrollment ID: O20190613001412 |
News Archive
In a paper recently uploaded to the preprint server medRxiv by Edward Málaga Trillo et al. (April 29th, 2021), these methods are tested in combination with CRISPR-Cas detection in the field, demonstrating a sensitivity and specificity of 93.8% and 99%, respectively.
A prison clinic in Thailand's Nong Khai province successfully has treated 110 inmates with tuberculosis following a six-month treatment course, but the disease remains a serious health challenge in prisons throughout Thailand, the Bangkok Post reports.
Hospitalization rates in New York City for patients with community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), a potentially deadly bacterial infection that is resistant to antibiotic treatment, more than tripled between 1997 and 2006, according to a report published in the July issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved a new indication for MICARDIS® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. MICARDIS® is the first treatment in its class to be approved for this indication.
New research finds genetic differences that help to explain why some babies are born bigger or smaller than others.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Portia S Carr, MS,CCC-SLP 7327 Worth Ave E, Benton, AR 72019-6895 Ph: (501) 773-7155 | Mrs Portia S Carr, MS,CCC-SLP 7327 Worth Ave E, Benton, AR 72019-6895 Ph: (501) 773-7155 |
News Archive
In a paper recently uploaded to the preprint server medRxiv by Edward Málaga Trillo et al. (April 29th, 2021), these methods are tested in combination with CRISPR-Cas detection in the field, demonstrating a sensitivity and specificity of 93.8% and 99%, respectively.
A prison clinic in Thailand's Nong Khai province successfully has treated 110 inmates with tuberculosis following a six-month treatment course, but the disease remains a serious health challenge in prisons throughout Thailand, the Bangkok Post reports.
Hospitalization rates in New York City for patients with community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), a potentially deadly bacterial infection that is resistant to antibiotic treatment, more than tripled between 1997 and 2006, according to a report published in the July issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved a new indication for MICARDIS® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. MICARDIS® is the first treatment in its class to be approved for this indication.
New research finds genetic differences that help to explain why some babies are born bigger or smaller than others.
› Verified 9 days ago
Arkansas Therapy Outreach, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3851 Legacy Village Dr, Benton, AR 72015 Phone: 501-350-7572 Fax: 501-776-4059 | |
Cassandra Powell, M.S.CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Park Dr, Benton, AR 72015 Phone: 501-315-0136 | |
Taylor Gibbs Crosby, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17706 Interstate 30 N Ste 3, Benton, AR 72019 Phone: 501-315-4414 | |
Ryan Russell, MSSLP.CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6701 Highway 67, Benton, AR 72015 Phone: 501-860-0777 | |
Rebekah Anne Kennedy, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17706 Interstate 30 N Ste 3, Benton, AR 72019 Phone: 501-315-4414 | |
Jessica Faye Huffty, MS, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3214 Winchester, Benton, AR 72015 Phone: 501-315-4414 Fax: 501-315-3467 | |
Mckenna Lynn Zeringue, M.S. CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17706 I 30, Benton, AR 72019 Phone: 501-315-4414 |